Clinical Trials Logo

Filter by:
NCT ID: NCT01151410 Completed - Hypertension Clinical Trials

An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age

Start date: August 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate in a randomized, double-blind fashion, the long-term safety, tolerability and efficacy profile of aliskiren compared to the active comparator enalapril in children, 6 - 17 years old with hypertension (msSBP ≥ 95th percentile for age, gender and height, at baseline in study CSPP100A2365). Patients will be randomized to receive either aliskiren or enalapril. Weight-group based doses of aliskiren or enalapril will be administered once daily and children will receive study medication in a double-blind manner. This study is being conducted to support monotherapy registration of aliskiren for the treatment of hypertension in pediatric patients 6-17 years of age (age at baseline in Study CSPP100A2365).

NCT ID: NCT01150448 Completed - Schizophrenia Clinical Trials

A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia

Start date: September 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the long term safety of flexible doses (50 to 150 mg equivalent) of paliperidone palmitate in the treatment of patients with schizophrenia and to document the pharmacokinetics of paliperidone following fixed multiple intramuscular injections of paliperidone palmitate 150 mg eq.

NCT ID: NCT01150357 Completed - Hypertension Clinical Trials

Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age

Start date: June 2010
Phase: Phase 3
Study type: Interventional

This double-blind 8 week study will evaluate dose response, efficacy (blood pressure lowering effect) and safety of aliskiren in children 6 - 17 years old with hypertension at low, mid and high weight-based doses. The low dose ranges from 6.25 mg to 25 mg of aliskiren, the mid dose ranges from 37.5 mg to 150 mg of aliskiren and the high dose ranges from 150 mg to 600 mg of aliskiren. This study is being conducted to support monotherapy registration of aliskiren for the treatment of hypertension in children 6-17 years of age.

NCT ID: NCT01147003 Completed - Clinical trials for Partial Onset Seizures

Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures

Start date: June 2010
Phase: Phase 2
Study type: Interventional

This study will assess the efficacy and safety of BGG492 as adjunctive treatment in patients with partial onset seizures.

NCT ID: NCT01144338 Completed - Clinical trials for Type 2 Diabetes Mellitus

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Start date: June 18, 2010
Phase: Phase 3
Study type: Interventional

This study will compare the impact of including exenatide once weekly in addition to usual care vs. usual care without exenatide on major cardiovascular outcomes as measured by the primary composite endpoint of cardiovascular-related death, nonfatal myocardial infarction (MI), or nonfatal stroke.

NCT ID: NCT01143324 Completed - Clinical trials for Lumbar Spine Degeneration

A Prospective, Multicenter Observational Study on MAST™ (Minimal Access Spinal Technologies) Fusion Procedures for the Treatment of the Degenerative Lumbar Spine

MASTERS-D
Start date: June 2010
Phase:
Study type: Observational

The aim of the study is to observe and document surgical practice and evaluate patients' outcomes following a MAST™ single or double level instrumented fusion procedure using PLIF (Posterior Lumbar Interbody Fusion) or TLIF (Transforaminal Lumbar Interbody Fusion) techniques for the treatment of the degenerative lumbar spine in a "real-world" patient population.

NCT ID: NCT01142674 Completed - Clinical trials for Lymphoma, T-Cell, Peripheral

T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma

Start date: September 2006
Phase:
Study type: Observational

The designed study follows up the retrospective previous one by the International T-cell Non-Hodgkin's Lymphoma Study Group (International Peripheral T-Cell Lymphoma Project). It is designed as a prospective collection of information potentially useful to predict the prognosis of newly diagnosed patients with the more frequent subtypes of Peripheral T-cell lymphoma (Peripheral T-cell lymphoma unspecified and Angioimmunoblastic T-cell lymphoma) and to better define clinical characteristics and outcome of the more uncommon subtypes

NCT ID: NCT01138098 Completed - Hepatitis B Clinical Trials

Evaluation of Antibody Persistence and Immune Memory Against the Hepatitis B Antigen in Previously Vaccinated Children

Start date: June 7, 2010
Phase: Phase 4
Study type: Interventional

This study will evaluate the persistence of immunity to hepatitis B 10 to 11 years after vaccination with Infanrix hexa™ or Engerix™-B and also the ability to mount an immune response to the challenge dose of Engerix™-B.

NCT ID: NCT01136382 Completed - Asthma Clinical Trials

A 6-week Study in Asthmatic Children Aged 6 to <12 Yrs Comparing Budesonide pMDI 160ug Twice Daily With Placebo

CHASE 1
Start date: July 2010
Phase: Phase 2
Study type: Interventional

This purpose of the study is to investigate if budesonide pMDI 160 �g twice a day during 6 weeks is effective and safe in treating asthmatic children aged 6 to <12 years

NCT ID: NCT01130844 Completed - Ulcerative Colitis Clinical Trials

Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis

Start date: October 8, 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and pharmacokinetics of MMX mesalamine following administration in children and adolescents with ulcerative colitis.